Prime Medicine's application will test an FDA that has promised to speed new gene-editing treatments but has recently spurned ...

The CRISPR gene editing system holds tremendous promise. It has already revolutionized biomedical research by making gene editing a straightforward process. It involves using a guide RNA molecule that ...

Researchers at ETH Zurich in Basel report they have used CRISPR-Cas technology to decipher how mutations in a cell’s genome affect its function. With their new approach, the researchers can generate ...

Prime Medicine has surged over 130% in three months, driven by pipeline progress and visibility from recent scientific presentations. PRME's Prime Editing platform targets multi-billion-dollar markets ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Prime Medicine, Inc. (NASDAQ:PRME) stands against the other CRISPR stocks.

Using prime editing, NCF1 mutation is corrected in a 19-year-old with chronic granulomatous disease, an inherited immune disorder, marking a gene therapy milestone.

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Prime Medicine, a Cambridge biotech whose ...

The U.S. Food and Drug Administration approved the first cell-based gene therapies for sickle cell disease, including the first-ever treatment built on CRISPR/Cas9 technology. That decision moved gene ...

Thank you, guys, for being here. Super excited to have an old friend join us for a new fireside chat. Allan, great to have you. And we all want to learn Prime Medicine and Prime Editing, but I'll let ...